Altimmune Stock Discussion

$Altimmune (ALT.US)$ Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Benzinga· 1 min ago
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...

$Altimmune (ALT.US)$
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor...

Another strong day for ALT. 7.65 is resistance now. Support is at 7.40 the top of the POC.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

$Altimmune (ALT.US)$ 👀looks food 1 month breakout
$Altimmune (ALT.US)$

Pushing up into the POC now. Here are the levels to keep an eye on this week.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

After consolidating in the POC for several days ALT has broken over the 6.45 resistance. Next stop is 6.77 if it continues up.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

$Altimmune (ALT.US)$
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...

Nice move up today sitting at the top of the POC now. Here are the levels to watch.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$

$Altimmune (ALT.US)$ hopefully just a steady rise from here